What is the recommended treatment plan for an adult with moderate-to-severe inflammatory bowel disease?

Treatment of Moderate-to-Severe Inflammatory Bowel Disease in Adults

For moderate-to-severe ulcerative colitis, initiate biologic therapy (infliximab or vedolizumab preferred) or tofacitinib over conventional step-up therapy with 5-aminosalicylates, and for moderate-to-severe Crohn's disease, use corticosteroids (prednisolone 40 mg daily) for induction followed by azathioprine/mercaptopurine as steroid-sparing agents, with infliximab reserved for refractory or fistulating disease. 1

Ulcerative Colitis Treatment Algorithm

First-Line Induction Therapy

Biologic-Naive Patients:

• Infliximab or vedolizumab are preferred over adalimumab for induction of remission 1
• Tofacitinib should only be used after failure of or intolerance to TNF antagonists per FDA guidance 1
• Early biologic use (with or without immunomodulators) is preferred over gradual step-up after 5-ASA failure 1

Previously Exposed to Infliximab:

• Use ustekinumab or tofacitinib rather than vedolizumab or adalimumab, particularly if primary non-response occurred 1

Combination vs. Monotherapy

Combine TNF antagonists, vedolizumab, or ustekinumab with thiopurines or methotrexate rather than using biologic monotherapy for enhanced efficacy 1. Patients with less severe disease who prioritize safety over maximal efficacy may reasonably choose monotherapy.

Conventional Therapy Considerations

• Avoid thiopurine monotherapy for induction of remission 1
• Avoid methotrexate monotherapy for either induction or maintenance 1
• For mild-moderate disease where biologics are declined: mesalazine 2-4 g daily or prednisolone 40 mg daily 2
• Prednisolone should be tapered over 8 weeks; more rapid reduction causes early relapse 2

Acute Severe Ulcerative Colitis (Hospitalized)

• IV methylprednisolone 40-60 mg/day (not higher doses) 1
• Avoid adjunctive antibiotics unless infection is documented 1
• For steroid-refractory disease: use infliximab or cyclosporine 1
• Joint gastroenterology-surgery management is mandatory 2

Maintenance Therapy

• Continue the agent that successfully induced remission 1
• Discontinue 5-ASA once remission is achieved with biologics/immunomodulators or tofacitinib 1
• Thiopurine monotherapy is acceptable for maintenance (not induction) 1

Crohn's Disease Treatment Algorithm

Active Ileal/Ileocolonic/Colonic Disease

Mild Disease:

• High-dose mesalazine 4 g daily may be sufficient 2

Moderate-to-Severe Disease:

• Prednisolone 40 mg daily for induction 2
• Taper gradually over 8 weeks 2
• Budesonide 9 mg daily for isolated ileocecal disease (marginally less effective than prednisolone) 2

Severe Disease:

• IV hydrocortisone 400 mg/day or methylprednisolone 60 mg/day 2
• Consider concomitant IV metronidazole to distinguish active disease from septic complications 2

Steroid-Sparing Strategy

• Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day as adjunctive therapy and steroid-sparing agents 2
• Slow onset of action precludes use as sole therapy 2

Biologic Therapy

• Infliximab 5 mg/kg is effective but avoid in patients with obstructive symptoms 2
• Reserve for steroid-refractory disease or as part of comprehensive management strategy

Fistulating and Perianal Disease

Simple Perianal Fistulae:

• Metronidazole 400 mg three times daily and/or ciprofloxacin 500 mg twice daily as first-line 2

Complex/Refractory Fistulae:

• Infliximab (three infusions of 5 mg/kg at 0,2, and 6 weeks) combined with immunomodulation and surgery 2
• Azathioprine/mercaptopurine for simple fistulae where obstruction and abscess excluded 2

Nutritional Support

• Elemental or polymeric diets are less effective than corticosteroids but acceptable for patients who refuse steroids 2
• Total parenteral nutrition as adjunctive therapy in complex fistulating disease 2

Critical Pitfalls to Avoid

Do not use corticosteroids for long-term maintenance in either UC or CD—they are for induction only 2. Patients requiring chronic steroids need azathioprine/mercaptopurine or biologic therapy.

Screen for tuberculosis before initiating anti-TNF therapy—reactivation risk is 4-fold higher (24/100,000 vs 6/100,000) 2. Avoid in patients with history of malignancy or existing cardiac failure 2.

Do not delay treatment waiting for stool cultures in acute presentations—infection can be excluded retrospectively 2.

Surgery should be considered early for limited ileal/ileocecal Crohn's disease or after medical therapy failure—inform UC patients of 25-30% colectomy risk 2.

Evidence Quality Considerations

The 2020 AGA guidelines 1 provide the most recent high-quality recommendations for UC, with strong evidence (moderate quality) supporting biologics and tofacitinib over no treatment. However, most comparative data between specific agents is conditional with low-to-moderate quality evidence, reflecting the complexity of treatment selection. The 2004 Gut guidelines 2 remain relevant for conventional therapy and CD management, though predating many newer biologics. The 2025 British Society of Gastroenterology guidelines 3 confirm the shift toward early advanced therapy and treat-to-target approaches prioritizing biochemical/endoscopic remission over symptomatic control.